This is not a stock tip!

While it is true as per Mr. Levitt's article that smaller, specialized companies may be greater beneficiaries of sales of genetically engineered pharmaceuticals, they are even more likely to benefit from genetic engineering of patients' tumors or lymphocytes.What isn't clear to me, particularly given Levitt's mention of Bristol-Myers-Squibb's acquisition of Medarex and Roche's of Genentech, is why the large pharmaceutical companies won't benefit in their usual manner by purchasing innovations.